echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > FP-025 for the treatment of COVID-19-related ARDS, Phase II/III clinical trials have officially started

    FP-025 for the treatment of COVID-19-related ARDS, Phase II/III clinical trials have officially started

    • Last Update: 2021-04-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Acute respiratory distress syndrome (ARDS), are serious infections , shock, trauma and burns and other disease processes, pulmonary capillary vascular endothelial cells and diffuse alveolar damage in alveolar epithelial cells in inflammatory damage caused, leading to acute hypoxic respiratory Insufficiency or failure.


    Infected blood vessels

    The pharmaceutical company Foresee announced today that its highly selective oral MMP-12 inhibitor FP-025 will be used to treat severe COVID-19 patients with acute respiratory distress syndrome (ARDS) in a Phase II/III clinical trial in adult patients.


    COVID-19

    The Phase II/III clinical trial is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of FP-025.


    Dr.


    FP-025 has shown significant therapeutic effects in preclinical inflammation and pulmonary fibrosis models, which indicates that FP-025 may avoid lung damage and fibrosis caused by COVID-19 infection.


    Original source:

    Original source:

    href="" target="_blank" rel="noopener">leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.